IPFA/PEI 20th International Workshop on. Surveillance and Screening of Blood Borne Pathogens

Transcription

1 xler 20 mins. IPFA/PEI 20th International Workshop on Surveillance and Screening of Blood Borne Pathogens HELSINKI AT standardization ONS t) 30 mins. In collaboration with the Finnish Red Cross Blood Service 20 th An niv April 2013 ers ary Crowne Plaza Helsinki, Finland Eve nt

2 programme DAY ONE Tuesday 23 April Session 1: OPENING SESSION Chair: Dr R. Perry 9.00 Session 2: KEY NOTE SESSION Chair: Dr M. Nübling Welcome and introduction Opening of the meeting Ms S. Rajaniemi (Finnish Medicines Agency) 10 mins. Evolution of the role of the Finnish Red Cross Blood Service in the national plasma product program Dr M. Syrjälä (FRCBS) 20 mins. THE EVOLUTION OF SCIENCE, IMPLICATIONS AND POLICY IN MICROBIAL SAFETY OF BLOOD PRODUCTS The evolution of safety and regulation Prof. J. Löwer (Past President Paul Ehrlich Institut) 30 mins. The evolution of science Dr M. Busch (Blood Systems Research Institute) 30 mins BREAK

3 10.45 Session 3: AVAILABILITY AND POTENTIAL USE OF PLASMA Chair: Prof. J-P. Allain IN DEVELOPING COUNTRIES Screening and clinical use of blood and blood components in developing countries Dr S. Owusu-Ofori (Komfo Anokye Teaching Hospital) 20 mins. Clinical need of plasma derivatives and availability of suitable plasma Dr J. Emmanuel (Blood Transfusion Medicine Consultant) 20 mins. Is fractionation of developing countries' plasma possible? Are there alternatives? Prof. T. Burnouf (Human Protein Process Sciences) 20 mins. Should the same rules apply to developed and developing countries plasma for preparation of derivatives? Prof. A. Farrugia (Plasma Protein Therapeutics Association) 20 mins. Panel debate LUNCH Kindly sponsored by Roche Diagnostics Session 4: MANAGEMENT OF RISK AND COSTS Chair: Prof. Dr H. Zaaijer Key-Note: How should regulators assess and manage risks of blood products? Dr J. Epstein (U.S. Food and Drug Administration) 30 mins.

4 Efficacy of donor deferral: Experiences from an EDQM working group Dr R. Norda (Uppsala University Hospital) 20 mins. What price negative test results in cost effectiveness analyses? Dr I. Franklin (Irish Blood Transfusion Service) 20 mins BREAK Session 5: UPDATE SESSION Chair: Dr T. Krusius West Nile Virus and other arboviruses in the USA Dr R. Dodd (American Red Cross) 20 mins. Surveillance of WNV and other emerging pathogens in Europe Dr D. Domanovic (European Centre for Disease Prevention and Control) 20 mins. Validation of prion removal systems and of vcjd tests for blood transfusion and blood products Dr J. Coste (Etablissement Français du Sang) 20 mins END OF DAY DEPARTURE FOR DINNER Kindly sponsored by Abbott

5 DAY TWO Wednesday 24 April Session 6: Chair: Dr J. Petrik MANUFACTURERS' SESSION Abbott Diagnostics: Application of Metagenomic Technologies for Viral Discovery and Surveillance - Dr J. Hackett 20 mins. GFE Blut: Recent developments for flexible NAT-testing concepts - Dr R. Thermann 20 mins. Novartis Diagnostics: Plasma Testing Solutions: Present & Future - Parvo/HAV Assay Validation - a Global Perspective Dr T. Gierman, Grifols 10 mins. - HEV Assay Development Update Dr J. Linnen, Hologic Gen-Probe 10 mins. Roche Diagnostics: And now for something completely new T.B.A. 20 mins. V.I.P.S.: S/D Mini-Pool "Lifeguard Services" Dr M. El Ekiaby 20 mins LUNCH Session 8: Chair: Dr M. Busc Session 9: BREAK Session 7: Chair: Mr J. Vincini HEV AND OTHER TROUBLESOME INFECTIOUS AGENTS HEV overview - virology, clinical issues and assay developments Dr H. Dalton 20 mins. HEV epidemiology - a European perspective Prof. Dr H. Zaaijer 20 mins.

6 ic Technologies ckett 20 mins. AT-testing : Present & Future ctive HEV - Implications for plasma products and NAT standardization Dr S. Baylis 20 mins. The risk of Zoonotic transmission - Dr J.F. Drexler 20 mins LUNCH Kindly sponsored by Terumo BCT Session 8: Chair: Dr M. Busch ASSESSMENT, PREDICTIONS AND SPECULATIONS FOR THE NEXT 10 YEARS Key-Note presentation Prof. F. Miedema (University Medical Center Utrecht) 30 mins. Looking into the future Prof. J-P. Allain 10 mins. Dr J. Epstein 10 mins. Dr M. Nübling 10 mins. Panel Debate Session 9: MEETING CLOSURE FAREWELL DRINKS mpletely new S AGENTS say developments THIS WORKSHOP IS KINDLY SPONSORED BY: Abbott Cerus Corporation DiaSorin GFE Blut Novartis Diagnostics Roche Diagnostics Terumo BCT V.I.P.S. IPFA Surveilla In 20 th An niv er